Skip to main content
Top
Published in: BMC Medical Informatics and Decision Making 1/2014

Open Access 01-12-2014 | Research article

Variability of the impact of adverse events on physicians’ decision making

Authors: Raluca Cozmuta, Peter A Merkel, Elizabeth Wahl, Liana Fraenkel

Published in: BMC Medical Informatics and Decision Making | Issue 1/2014

Login to get access

Abstract

Background

Physicians frequently differ in their treatment recommendations. However, few studies have examined the reasons underlying these differences. The objective of this study was to examine whether physicians vary in the importance they attach to specific adverse events for two treatment options found in recent randomized controlled trials to have equivalent efficacy and overall toxicity.

Methods

A Max-Diff survey was administered to physicians attending a national scientific conference to quantify the influence of 23 specific adverse events on decision making related to two treatment options for vasculitis. This approach was chosen because it results in greater item discrimination compared to rating scales. We used Hierarchical Bayes modeling to generate the relative importance score for each adverse event and examined the association between physicians’ characteristics and the five most influential factors.

Results

118 physicians completed the survey. The mean age (SD) was 48 years (10); 68% were male and 81% reported spending the majority of time in clinical practice. There was significant variability in the ratings of the relative importance of all adverse events, except those that were mild and easily reversible. We found a positive correlation between increasing physician age with ratings of sepsis (r = 0.29, p = 0.002) and opportunistic infection (r = 0.23, p = 0.016), and an inverse association between age with progressive multifocal leukoencephalopathy (r = - 0.28, p = 0.003). Physician sex, work setting, location, and number of patients with vasculitis seen per year were not associated with the influence of specific adverse events on decision making.

Conclusion

Our findings demonstrate that physicians differ substantially in how they perceive the importance of specific adverse events which may help explain observed unwarranted variability in physicians’ recommendations in clinical practice. Further efforts are needed to ensure that the reasons underlying variability in physicians’ recommendations are transparent.
Appendix
Available only for authorised users
Literature
1.
go back to reference Kachalia A, Mello MM: Breast cancer screening: conflicting guidelines and medicolegal risk. JAMA. 2013, 309: 2555-2556. 10.1001/jama.2013.7100.CrossRefPubMed Kachalia A, Mello MM: Breast cancer screening: conflicting guidelines and medicolegal risk. JAMA. 2013, 309: 2555-2556. 10.1001/jama.2013.7100.CrossRefPubMed
3.
go back to reference Stone JH, Merkel PA, Spiera R, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, Kallenberg CGM, St Clair EW, Turkiewicz A, Tchao NK, Webber L, Ding L, Sejismundo LP, Mieras K, Weitzenkamp D, Ikle D, Seyfert-Margolis V, Mueller M, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh KA, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Specks U, for the RAVE-ITN Research Group: Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010, 363: 221-232. 10.1056/NEJMoa0909905.CrossRefPubMedPubMedCentral Stone JH, Merkel PA, Spiera R, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, Kallenberg CGM, St Clair EW, Turkiewicz A, Tchao NK, Webber L, Ding L, Sejismundo LP, Mieras K, Weitzenkamp D, Ikle D, Seyfert-Margolis V, Mueller M, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh KA, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Specks U, for the RAVE-ITN Research Group: Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010, 363: 221-232. 10.1056/NEJMoa0909905.CrossRefPubMedPubMedCentral
4.
go back to reference Jones RB, Tervaert JWC, Hauser T, Luqmani R, Morgan MD, Peh CA, Savage CO, Segelmark M, Tesar V, van Paassen P, Walsh D, Walsh M, Westman K, Jayne DRW, for the European Vasculitis Study Group: Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010, 363: 211-220. 10.1056/NEJMoa0909169.CrossRefPubMed Jones RB, Tervaert JWC, Hauser T, Luqmani R, Morgan MD, Peh CA, Savage CO, Segelmark M, Tesar V, van Paassen P, Walsh D, Walsh M, Westman K, Jayne DRW, for the European Vasculitis Study Group: Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010, 363: 211-220. 10.1056/NEJMoa0909169.CrossRefPubMed
5.
go back to reference Anolik JH, Barnard J, Cappione A, Pugh-Bernard AE, Felgar RE, Looney RJ, Sanz I: Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum. 2004, 50: 3580-3590. 10.1002/art.20592.CrossRefPubMed Anolik JH, Barnard J, Cappione A, Pugh-Bernard AE, Felgar RE, Looney RJ, Sanz I: Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum. 2004, 50: 3580-3590. 10.1002/art.20592.CrossRefPubMed
6.
go back to reference Balow JE: Choosing treatment for proliferative lupus nephritis. Arthritis Rheum. 2002, 46: 1981-1983. 10.1002/art.10466.CrossRefPubMed Balow JE: Choosing treatment for proliferative lupus nephritis. Arthritis Rheum. 2002, 46: 1981-1983. 10.1002/art.10466.CrossRefPubMed
7.
go back to reference Boren EJ, Cheema GS, Naguwa SM, Ansari AA, Gershwin ME: The emergence of progressive multifocal leukoencephalopathy (PML) in rheumatic diseases. J Autoimmun. 2008, 30: 90-98. 10.1016/j.jaut.2007.11.013.CrossRefPubMed Boren EJ, Cheema GS, Naguwa SM, Ansari AA, Gershwin ME: The emergence of progressive multifocal leukoencephalopathy (PML) in rheumatic diseases. J Autoimmun. 2008, 30: 90-98. 10.1016/j.jaut.2007.11.013.CrossRefPubMed
8.
go back to reference Boumpas DT, Austin HA, Balow JE, Vaughan EM, Yarboro CH, Klippel JH, Steinberg AD: Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet. 1992, 340: 741-745. 10.1016/0140-6736(92)92292-N.CrossRefPubMed Boumpas DT, Austin HA, Balow JE, Vaughan EM, Yarboro CH, Klippel JH, Steinberg AD: Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet. 1992, 340: 741-745. 10.1016/0140-6736(92)92292-N.CrossRefPubMed
9.
go back to reference Cohen P, Pagnoux C, Mahr A, Arène JP, Mouthon L, Le Guern V, André MH, Gayraud M, Jayne D, Blöckmans D, Cordier JF, Guillevin L, French Vasculitis Study Group: Churg-Strauss syndrome with poor-prognosis factors: a prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in forty-eight patients. Arthritis Rheum. 2007, 57: 686-693. 10.1002/art.22679.CrossRefPubMed Cohen P, Pagnoux C, Mahr A, Arène JP, Mouthon L, Le Guern V, André MH, Gayraud M, Jayne D, Blöckmans D, Cordier JF, Guillevin L, French Vasculitis Study Group: Churg-Strauss syndrome with poor-prognosis factors: a prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in forty-eight patients. Arthritis Rheum. 2007, 57: 686-693. 10.1002/art.22679.CrossRefPubMed
10.
go back to reference De Groot K, Harper L, Jayne DR, Flores Suarez LF, Gregorini G, Gross WL, Luqmani R, Pusey CD, Rasmussen N, Sinico RA, Tesar V, Vanhille P, Westman K, Savage CO, EUVAS (European Vasculitis Study Group): Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis. Ann Intern Med. 2009, 150: 670-680. 10.7326/0003-4819-150-10-200905190-00004.CrossRefPubMed De Groot K, Harper L, Jayne DR, Flores Suarez LF, Gregorini G, Gross WL, Luqmani R, Pusey CD, Rasmussen N, Sinico RA, Tesar V, Vanhille P, Westman K, Savage CO, EUVAS (European Vasculitis Study Group): Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis. Ann Intern Med. 2009, 150: 670-680. 10.7326/0003-4819-150-10-200905190-00004.CrossRefPubMed
11.
go back to reference De Groot K, Rasmussen N, Bacon PA, Tervaert JW, Feighery C, Gregorini G, Gross WL, Luqmani R, Jayne DR: Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2005, 52: 2461-2469. 10.1002/art.21142.CrossRefPubMed De Groot K, Rasmussen N, Bacon PA, Tervaert JW, Feighery C, Gregorini G, Gross WL, Luqmani R, Jayne DR: Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2005, 52: 2461-2469. 10.1002/art.21142.CrossRefPubMed
12.
go back to reference Fauci AS, Haynes BF, Katz P, Wolff SM: Wegener’s granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Internal Med. 1983, 98: 76-85. 10.7326/0003-4819-98-1-76.CrossRef Fauci AS, Haynes BF, Katz P, Wolff SM: Wegener’s granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Internal Med. 1983, 98: 76-85. 10.7326/0003-4819-98-1-76.CrossRef
13.
go back to reference Faurschou M, Sorensen IJ, Mellemkjaer L, Loft AG, Thomsen BS, Tvede N, Baslund B: Malignancies in Wegener’s granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. J Rheumatol. 2008, 35: 100-105.PubMed Faurschou M, Sorensen IJ, Mellemkjaer L, Loft AG, Thomsen BS, Tvede N, Baslund B: Malignancies in Wegener’s granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. J Rheumatol. 2008, 35: 100-105.PubMed
14.
go back to reference Ginzler EM, Dooley MA, Aranow C, Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT, Petri M, Gilkeson GS, Wallace DJ, Weisman MH, Appel GB: Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med. 2005, 53: 2219-2228.CrossRef Ginzler EM, Dooley MA, Aranow C, Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT, Petri M, Gilkeson GS, Wallace DJ, Weisman MH, Appel GB: Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med. 2005, 53: 2219-2228.CrossRef
15.
go back to reference Gunnarsson I, Sundelin B, Jonsdottir T, Jacobson SH, Henriksson EW, van Vollenhoven RF: Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. Arthritis Rheum. 2007, 56: 1263-1272. 10.1002/art.22505.CrossRefPubMed Gunnarsson I, Sundelin B, Jonsdottir T, Jacobson SH, Henriksson EW, van Vollenhoven RF: Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. Arthritis Rheum. 2007, 56: 1263-1272. 10.1002/art.22505.CrossRefPubMed
16.
go back to reference Houssiau FA, Vasconcelos C, D’Cruz D, Sebastiani GD, Garrido Ed Ede R, Danieli MG, Abramovicz D, Blockmans D, Mathieu A, Direskeneli H, Galeazzi M, Gül A, Levy Y, Petera P, Popovic R, Petrovic R, Sinico RA, Cattaneo R, Font J, Depresseux G, Cosyns JP, Cervera R: Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum. 2002, 46: 2121-2131. 10.1002/art.10461.CrossRefPubMed Houssiau FA, Vasconcelos C, D’Cruz D, Sebastiani GD, Garrido Ed Ede R, Danieli MG, Abramovicz D, Blockmans D, Mathieu A, Direskeneli H, Galeazzi M, Gül A, Levy Y, Petera P, Popovic R, Petrovic R, Sinico RA, Cattaneo R, Font J, Depresseux G, Cosyns JP, Cervera R: Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum. 2002, 46: 2121-2131. 10.1002/art.10461.CrossRefPubMed
17.
go back to reference Jayne D: Review article: progress of treatment in ANCA-associated vasculitis. Nephrology. 2009, 14: 42-48. 10.1111/j.1440-1797.2009.01101.x.CrossRefPubMed Jayne D: Review article: progress of treatment in ANCA-associated vasculitis. Nephrology. 2009, 14: 42-48. 10.1111/j.1440-1797.2009.01101.x.CrossRefPubMed
18.
go back to reference Jayne DR, Rasmussen N: Treatment of antineutrophil cytoplasm autoantibody-associated systemic vasculitis: initiatives of the European community systemic vasculitis clinical trials study group. Mayo Clin Proc. 1997, 72: 737-747. 10.1016/S0025-6196(11)63594-5.CrossRefPubMed Jayne DR, Rasmussen N: Treatment of antineutrophil cytoplasm autoantibody-associated systemic vasculitis: initiatives of the European community systemic vasculitis clinical trials study group. Mayo Clin Proc. 1997, 72: 737-747. 10.1016/S0025-6196(11)63594-5.CrossRefPubMed
19.
go back to reference Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, Utset TO, Gordon C, Isenberg DA, Hsieh HJ, Zhang D, Brunetta PG: Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010, 62: 222-233. 10.1002/art.27233.CrossRefPubMedPubMedCentral Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, Utset TO, Gordon C, Isenberg DA, Hsieh HJ, Zhang D, Brunetta PG: Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010, 62: 222-233. 10.1002/art.27233.CrossRefPubMedPubMedCentral
20.
go back to reference Mok CC, Ho CTK, Chan KW, Lau CS, Wong RWS: Outcome and prognostic indicators of diffuse proliferative lupus glomerulonephritis treated with sequential oral cyclophosphamide and azathioprine. Arthritis Rheum. 2002, 46: 1003-1013. 10.1002/art.10138.CrossRefPubMed Mok CC, Ho CTK, Chan KW, Lau CS, Wong RWS: Outcome and prognostic indicators of diffuse proliferative lupus glomerulonephritis treated with sequential oral cyclophosphamide and azathioprine. Arthritis Rheum. 2002, 46: 1003-1013. 10.1002/art.10138.CrossRefPubMed
21.
go back to reference Mukhtyar C, Flossmann O, Hellmich B, Bacon P, Cid M, Cohen-Tervaert JW, Gross WL, Guillevin L, Jayne D, Mahr A, Merkel PA, Raspe H, Scott D, Witter J, Yazici H, Luqmani RA, European Vasculitis Study Group (EUVAS): Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European league against rheumatism systemic vasculitis task force. Ann Rheum Dis. 2008, 67: 1004-1010. 10.1136/ard.2007.071936.CrossRefPubMed Mukhtyar C, Flossmann O, Hellmich B, Bacon P, Cid M, Cohen-Tervaert JW, Gross WL, Guillevin L, Jayne D, Mahr A, Merkel PA, Raspe H, Scott D, Witter J, Yazici H, Luqmani RA, European Vasculitis Study Group (EUVAS): Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European league against rheumatism systemic vasculitis task force. Ann Rheum Dis. 2008, 67: 1004-1010. 10.1136/ard.2007.071936.CrossRefPubMed
22.
go back to reference Radis CD, Kahl LE, Baker GL, Wasko MC, Cash JM, Gallatin A, Stolzer BL, Agarwal AK, Medsger TA, Kwoh CK: Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis a 20-year followup study. Arthritis Rheum. 1995, 38: 1120-1127. 10.1002/art.1780380815.CrossRefPubMed Radis CD, Kahl LE, Baker GL, Wasko MC, Cash JM, Gallatin A, Stolzer BL, Agarwal AK, Medsger TA, Kwoh CK: Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis a 20-year followup study. Arthritis Rheum. 1995, 38: 1120-1127. 10.1002/art.1780380815.CrossRefPubMed
23.
go back to reference Somers EC, Marder W, Christman GM, Ognenovski V, McCune WJ: Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus. Arthritis Rheum. 2005, 52: 2761-2767. 10.1002/art.21263.CrossRefPubMed Somers EC, Marder W, Christman GM, Ognenovski V, McCune WJ: Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus. Arthritis Rheum. 2005, 52: 2761-2767. 10.1002/art.21263.CrossRefPubMed
24.
go back to reference Stasi R, Stipa E, Del Poeta G, Amadori S, Newland AC, Provan D: Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab. Rheumatology. 2006, 45: 1432-1436. 10.1093/rheumatology/kel098.CrossRefPubMed Stasi R, Stipa E, Del Poeta G, Amadori S, Newland AC, Provan D: Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab. Rheumatology. 2006, 45: 1432-1436. 10.1093/rheumatology/kel098.CrossRefPubMed
25.
go back to reference Talar-Williams C, Hijazi YM, Walther MM, Linehan WM, Hallahan CW, Lubensky I, Kerr GS, Hoffman GS, Fauci AS, Sneller MC: Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener Granulomatosis. Ann Intern Med. 1996, 124: 477-484. 10.7326/0003-4819-124-5-199603010-00003.CrossRefPubMed Talar-Williams C, Hijazi YM, Walther MM, Linehan WM, Hallahan CW, Lubensky I, Kerr GS, Hoffman GS, Fauci AS, Sneller MC: Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener Granulomatosis. Ann Intern Med. 1996, 124: 477-484. 10.7326/0003-4819-124-5-199603010-00003.CrossRefPubMed
26.
go back to reference Tamimoto Y, Horiuchi T, Tsukamoto H, Otsuka J, Mitoma H, Kimoto Y, Nakashima H, Muta K, Abe Y, Kiyohara C, Ueda A, Nagasawa K, Yoshizawa S, Shimoda T, Harada M: A dose-escalation study of rituximab for treatment of systemic lupus erythematosus and Evans’ syndrome: immunological analysis of B cells, T cells and cytokines. Rheumatology. 2008, 47: 821-827. 10.1093/rheumatology/ken071.CrossRefPubMed Tamimoto Y, Horiuchi T, Tsukamoto H, Otsuka J, Mitoma H, Kimoto Y, Nakashima H, Muta K, Abe Y, Kiyohara C, Ueda A, Nagasawa K, Yoshizawa S, Shimoda T, Harada M: A dose-escalation study of rituximab for treatment of systemic lupus erythematosus and Evans’ syndrome: immunological analysis of B cells, T cells and cytokines. Rheumatology. 2008, 47: 821-827. 10.1093/rheumatology/ken071.CrossRefPubMed
27.
go back to reference van Herk H, Poortinga YH, Verhallen TMM: Response styles in rating scales. J Cross Cult Psychol. 2004, 35: 346-360. 10.1177/0022022104264126.CrossRef van Herk H, Poortinga YH, Verhallen TMM: Response styles in rating scales. J Cross Cult Psychol. 2004, 35: 346-360. 10.1177/0022022104264126.CrossRef
28.
go back to reference Flynn T, Louviere J, Peters T, Coast J: Best-worst scaling: what it can do for health care research and how to do it. J Health Econ. 2007, 26: 171-189. 10.1016/j.jhealeco.2006.04.002.CrossRefPubMed Flynn T, Louviere J, Peters T, Coast J: Best-worst scaling: what it can do for health care research and how to do it. J Health Econ. 2007, 26: 171-189. 10.1016/j.jhealeco.2006.04.002.CrossRefPubMed
32.
go back to reference Bharat A, Xie F, Baddley JW, Beukelman T, Chen L, Calabrese L, Delzell E, Grijalva CG, Patkar NM, Saag K, Winthrop KL, Curtis JR: Incidence and risk factors for progressive multifocal leukoencephalopathy among patients with selected rheumatic diseases. Arthritis Care Res. 2012, 64: 612-615. 10.1002/acr.21564.CrossRef Bharat A, Xie F, Baddley JW, Beukelman T, Chen L, Calabrese L, Delzell E, Grijalva CG, Patkar NM, Saag K, Winthrop KL, Curtis JR: Incidence and risk factors for progressive multifocal leukoencephalopathy among patients with selected rheumatic diseases. Arthritis Care Res. 2012, 64: 612-615. 10.1002/acr.21564.CrossRef
33.
go back to reference Molloy ES: PML and rheumatology: the contribution of disease and drugs. Clevel Clin J Med. 2011, 78 (Suppl 2): S28-S32.CrossRef Molloy ES: PML and rheumatology: the contribution of disease and drugs. Clevel Clin J Med. 2011, 78 (Suppl 2): S28-S32.CrossRef
Metadata
Title
Variability of the impact of adverse events on physicians’ decision making
Authors
Raluca Cozmuta
Peter A Merkel
Elizabeth Wahl
Liana Fraenkel
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Medical Informatics and Decision Making / Issue 1/2014
Electronic ISSN: 1472-6947
DOI
https://doi.org/10.1186/1472-6947-14-86

Other articles of this Issue 1/2014

BMC Medical Informatics and Decision Making 1/2014 Go to the issue